Warren’s words on pharma don’t play so well at home
Sen. Elizabeth Warren’s tough stance on the drug industry has won her plaudits in progressive circles. But in her home state of Massachusetts, where health care is an economic pillar, taking on pharma isn’t such a winning strategy.
As STAT’s Lev Facher and the Boston Globe’s Liz Goodwin report, Warren’s relationship has gradually moved from sympathetic to adversarial. In her first four years as a senator, Warren’s health care work was largely incremental and bipartisan. But that would change starting in 2015, when Warren dismissed the bipartisan 21st Century Cures Act as a “handout” for the drug industry.
The years that followed, Warren signed onto Sanders’ Medicare-for-All proposal, and introduced legislation to allow the federal government to manufacture generic drugs, positions that have further alienated her local pharmaceutical industry.
“Senator Warren was once receptive to the concerns of the Massachusetts biopharma community, but in recent years her advocacy and language on drug pricing have become more inflamed, demonizing her constituents who work in biopharma,” said Bob Coughlin, the head of the lobbying group MassBio.
Read more.
As STAT’s Lev Facher and the Boston Globe’s Liz Goodwin report, Warren’s relationship has gradually moved from sympathetic to adversarial. In her first four years as a senator, Warren’s health care work was largely incremental and bipartisan. But that would change starting in 2015, when Warren dismissed the bipartisan 21st Century Cures Act as a “handout” for the drug industry.
The years that followed, Warren signed onto Sanders’ Medicare-for-All proposal, and introduced legislation to allow the federal government to manufacture generic drugs, positions that have further alienated her local pharmaceutical industry.
“Senator Warren was once receptive to the concerns of the Massachusetts biopharma community, but in recent years her advocacy and language on drug pricing have become more inflamed, demonizing her constituents who work in biopharma,” said Bob Coughlin, the head of the lobbying group MassBio.
Read more.
No hay comentarios:
Publicar un comentario